NeoGenomics, Inc.
NEO · NASDAQ
Market closed$14.61$-0.230000 (-1.55%)After hours $14.75 · +0.96%
Key statistics
Previous close$14.84
Open$14.70
Day high$15.04
Day low$14.35
52-week high$15.57
52-week low$4.72
Market cap380.48M
Volume10.57M
Average volume2.72M
P/E ratio112.38
Forward P/E—
EPS0.13
Dividend yield0.00%
Market context
Why it moved
NEO declined amid a broad market selloff driven by growing concerns over AI spending, weakening semiconductor sentiment, and escalating geopolitical tensions in the Strait of Hormuz that weighed heavily on tech and growth-oriented stocks.
What is happening
Recent company-specific developments and publisher coverage.
Simply Wall Street · July 16, 2026NeoGenomics (NEO) Launches PTEN IHC CDx, Does The Valuation Still Look Full?TradingView · July 16, 2026PRPO vs. NEO: Which Cancer Diagnostics Stock Is the Better Buy?TradingView · July 13, 2026NeoGenomics, Inc. Stock 12‑Month Price Target Raised to $15.67, Implies 11% UpsideMoomoo · July 13, 2026BofA Securities Maintains NeoGenomics(NEO.US) With Hold Rating, Raises Target Price to $16Business Wire · July 9, 2026NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate CancerBusiness Wire · July 7, 2026NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026Clinical Lab Products · March 16, 2026NeoGenomics’ PanTracer LBx Test Qualifies for Medicare Coverage Under MolDX Policy Benzinga · July 9, 2026NeoGenomics Launches PTEN IHC CDx, Immunohistochemistry Companion Diagnostic Test Approved By FDA For Patients With Prostate Adenocarcinoma Mt Newswire · June 17, 2026NeoGenomics Prices $275 Million Offering of Convertible Notes Due 2032 Benzinga · June 17, 2026NeoGenomics Prices Offering Of $275M Of 0.75% Convertible Senior Notes Due 2032 Benzinga · June 15, 2026NeoGenomics Commences A Private Offering Of $275M Aggregate Principal Amount Of Convertible Senior Notes Due 2032 Mt Newswire · June 15, 2026NeoGenomics Reports Convertible Notes Offering Benzinga · May 26, 2026NeoGenomics To Showcase Eight Scientific Abstracts, Highlighting Advances In MRD, Precision Oncology, And Real-World Evidence Across Solid Tumors And Hematologic Malignancies, At 2026 ASCO Annual Meeting Benzinga · April 29, 2026Benchmark Upgrades NeoGenomics to Buy, Announces $11 Price Target Benzinga · April 29, 2026TD Cowen Maintains Buy on NeoGenomics, Raises Price Target to $14